Updates and Developments in Oncology
2007
Hepatocyte Growth Factor and Its Receptor in Cancer Therapies
publication
Evidence: moderate
Author Information
Author(s): W.G. Jiang
Primary Institution: Wales College of Medicine, Cardiff University
Hypothesis
Can targeting hepatocyte growth factor (HGF) and its receptor cMet improve cancer therapies?
Conclusion
HGF and its receptor are key players in cancer progression and present promising targets for therapeutic intervention.
Supporting Evidence
- HGF is overexpressed in nearly all human solid tumors.
- The combination of HGF and its receptor in cancer cells predicts a more aggressive tumor type.
- Targeting HGF and cMet may provide new therapeutic options for cancer treatment.
Takeaway
HGF helps cancer cells grow and spread, so scientists are looking for ways to block it to help treat cancer.
Limitations
The article discusses the potential of HGF and cMet in cancer therapies but does not provide specific clinical trial data.
Want to read the original?
Access the complete publication on the publisher's website